How a cell therapy helped change the course of my cancer reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
This May be a Safer Way for Millions to Treat Arthritic Pain
Millions of people all over the world deal with arthritic pain. In fact, just in the U.S., the Centers for Disease Control and Prevention (CDC), says about 23% of adults are dealing with it. Nearly 24 million are limited with their activities because of it, with about 25% of people reporting severe joint pain. To treat it, millions turn to NSAIDs, or non-steroidal anti-inflammatory drugs, which can actually make things far worse with potential gastrointestinal (GI) issues and intestinal injuries in some cases. However, companies like
Antibe Therapeutics Inc. (TSX: ATE) (OTCQX: ATBPF),
Operator
Good day, and welcome to the Bristol-Myers Squibb 2021 first-quarter results conference call. Today s conference is being recorded. At this time, I would like to turn the conference over to Mr. Tim Power, vice president of investor relations.
Please go ahead, sir.
Vice President, Investor Relations
Thanks, Keith. And good morning, everyone. Thanks for joining us today for our first-quarter 2021 earnings call. Joining me this morning with prepared remarks are Giovanni Caforio, our board chair and chief executive officer; and David Elkins, our chief financial officer.
Also participating in today s call for Q&A are Chris Boerner, our chief commercialization officer; and Samit Hirawat, our chief medical officer and head of global drug development. As you will see, we ve posted slides to bms.com that you can use to follow along with for today s remarks. But before we get started, let me read our forward-looking statements. During this call, we ll make statements about the co
By Reuters Staff
2 Min Read
NEW YORK (Reuters) - Bristol Myers Squibb said on Monday that its current drug pipeline has the ability to replace up to $25 billion a year in lost revenue from patent expirations by the end of the decade.
According to a presentation for JP Morgan’s annual healthcare conference, the company said anemia drug Reblozyl, as well as experimental heart drug mavacamten, psoriasis drug deucravacitinib and its cancer cell therapy franchise could each be responsible for more than $4 billion a year in revenue. Other drugs in the pipeline would make up the rest.
Reblozyl and one of the cancer cell therapies were picked up in the company’s $74 billion acquisition of Celgene last year. It acquired mavacamten this year in a $13 billion purchase of MyoKardia Inc.